Open Access
Access granted
Subscription or Fee Access
No 10 (2015)
- Year: 2015
- Articles: 15
- URL: https://journals.eco-vector.com/2073-4034/issue/view/6942
Articles
NOVOSTI MEDITsINY
Pharmateca. 2015;(10):4-7
4-7
Sindrom gipotireoza
Abstract
This article discusses the etiology, pathogenesis, clinical manifestations and treatment of hypothyroidism. As a substitution therapy, preparations containing thyroid hormones are used. The most common drug is levothyroxine. The use of combined drugs of triiodothyronine and thyroxine is also recomended.
Pharmateca. 2015;(10):8-11
8-11
Farmakoterapiya tyazheloy bronkhial'noy astmy
Abstract
Bronchial asthma is one of the most common inflammatory diseases of the airways. Increasing incidence rates, growing number of severe resistant to treatment cases and unchanging mortality rates make bronchial asthma an important medical and social problem. Consequently, prevention and treatment of bronchial asthma especially its severe forms are real challenges in public health.
Pharmateca. 2015;(10):12-15
12-15
Profilaktika i terapiya disbioticheskikh narusheniy kishechnika primeneniem probioticheskikh sredstv
Abstract
This article discusses the basic concepts of the modern state of normal human intestinal microflora, its composition, properties and functions in different parts of the intestine. The definition of the term «intestinal dysbiosis» is presented; a number of diseases associated with dysbiosis are discussed. The main characteristics of modern probiotics are described, their role in the prevention and treatment of dysbiotic intestinal disorders, including antibiotic-associated diarrhea, is discussed.
Pharmateca. 2015;(10):16-19
16-19
Mnogotselevaya terapiya sindroma razdrazhennogo kishechnika: sovremennyy vzglyad na reshenie problemy
Abstract
The article presents the analysis of the evidence base of treatment of irritable bowel syndrome (IBS). A large number of randomized, placebo-controlled trials systematized in several meta-analyzes show the effectiveness of monotherapy treatment regimens. Because IBS has a multifactorial pathogenesis with respect to triggers and pathogenetical ways, we suppose that for the majority of IBS patients need for combined and even personalized approaches to the treatment affecting several components of pathogenesis. This viewpoint is confirmed by international publications in recent years. The choice of pharmacotherapy of IBS in each case is a difficult decision, because it is determined by the form of the syndrome, the availability of a proven drug in the internal market, indications and the possibility of long-term use, high safety, and effectiveness according to the evidence-based criteria. In clinical practice, the use of traditional pharmacotherapy supplemented with specific herbal medicine or other types of complementary and alternative therapy can provide a better treatment outcome and significantly affect the quality of life of these patients. The potentials for the application of phytopreparation Iberogast®, which is a mixture of herbal extracts of nine plants, is considered in IBS.
Pharmateca. 2015;(10):20-25
20-25
Zapor v pozhilom vozraste: prichiny i lechenie
Abstract
The article presents the current diagnostic criteria for chronic constipation, features of diagnosis and treatment of constipation in middle-aged and elderly patients; the analysis of the results of recent research on the effectiveness of different groups of pharmacological agents in the treatment of constipation is demonstrated.
Pharmateca. 2015;(10):26-30
26-30
Primenenie enterosorbentov v lechenii kishechnykh infektsiy u detey s soputstvuyushchim atopicheskim dermatitom
Abstract
Acute intestinal infections (AII) are the second group of infectious diseases in children, with great importance and high prevalence. Malnutrition and malabsorption, immunodeficiencies and allergic diseases of the child have a significant impact on the course, prognosis and outcome of the AII. In recent years, the incidence of atopic dermatitis and food allergies in the pediatric population has significantly increased, that determines the need for development the ways to improve the effectiveness of topical therapy for this group of patients with infectious diseases. The article presents the results of the evaluation of clinical and laboratory efficiency of enterosorbents (diosmectit and polymethylsiloxane polyhydrate) in the treatment of AII in children with concomitant atopic dermatitis. The results indicate a high clinical and laboratory efficiency of enterosorbents which provide more rapid relief of symptoms of intoxication and fever, reduce the time of normalization of the feces, as well as reduce the risk of exacerbation and the severity of the clinical manifestations of concomitant allergic diseases with early initiation of therapy.
Pharmateca. 2015;(10):31-35
31-35
Kliniko-ekonomicheskie aspekty effektivnosti primeneniya Kavintona i Kavintona forte u bol'nykh s khronicheskoy ishemiey mozga. Issledovanie «KVADRA»
Abstract
The study was aimed to the evaluation of the efficacy and safety of a new treatment regimen with drugs Cavinton and Cavinton forte in patients with chronic cerebral ischemia (CCI). Main group (120 patients) received injectable Cavinton for 7 days, then oral Cavinton for 90 days along with standard therapy. The control group (120 patients) received only standard therapy. Analysis of efficiency was performed with account of dynamics of scale scoring in accordance to the study protocol. Safety was assessed based on the analysis of changes in neurological status, vital signs, parameters of vital functions, ECG and laboratory tests, as well as by analyzing of adverse events occurred. The clinical and economic evaluation of the cost of therapy in patients with CCI was performed. The results of study allow to recommend a new treatment regimen using Cavinton and Cavinton forte as an effective, safe and economically viable therapy in patients with CCI.
Pharmateca. 2015;(10):36-44
36-44
Primenenie Mildronata u patsientov s tserebrovaskulyarnoy patologiey
Abstract
The article presents the results of the evaluation of the effect of Mildronate at a daily dose of 500 mg (intravenously) as a part of basic therapy during the first 10 days of treatment, and at a daily dose of 1000 mg (orally) for 4 weeks on cognitive performance, coagulation and lipid profiles of 63 patients with cerebral discirculations. It was shown that study group had significantly lower lipid levels and better normalization of hemostatic parameters compared to control group, which were reflected on neurological characteristics of patients.
Pharmateca. 2015;(10):45-48
45-48
Ingibitory dipeptidilpeptidazy-4: novye vozmozhnosti effektivnogo glikemicheskogo kontrolya putem korrektsii narusheniy zhirovogo obmena u patsientov s sakharnym diabetom 2 tipa
Abstract
The article presents the results of the study, which was aimed to the evaluation of the effect of sitagliptin in combination with metformin on parameters of lipid metabolism in patients with type 2 diabetes mellitus. The study included 82 patients (55.3±9.1 years) who have not reached the target glycated hemoglobin levels, with overweight and dyslipidemia. The first group (42 individuals) have received sitagliptin 100 mg/day in combination with metformin 2.0 g/day; before entering the study, patients have received monotherapy with metformin 1.5-2.0 g/day. The second group (40 patients) have received monotherapy with metformin 2.0 g/day; before entering the study, these patients were on diet therapy. Fasting glucose levels, postprandial glucose, HbA1c, body weight, body mass index, waist circumference, waist circumference/hip circumference, lipid profile, insulin, leptin, adiponectin, HOMAIR (insulin resistance index), HOMA-ß (ß-pancreatic cells functional activity index) were assessed at baseline and at 6 months. MRI of visceral fat was performed. Against the background of combined therapy with sitagliptin and metformin, more pronounced important nonglicemic effects in the form of reduced visceral fat depot, increase of adiponectin levels and decrease of leptin levels were observed compared to monotherapy with metformin.
Pharmateca. 2015;(10):49-54
49-54
Vozmozhnosti neyroprotektsii posleoperatsionnykh kognitivnykh disfunktsiy posle koronarnogo shuntirovaniya: rezul'taty shestimesyachnogo nablyudeniya
Abstract
The article presents the analysis of cognitive impairment in 60 patients with coronary artery disease in the early postoperative period and 6 months after coronary artery bypass surgery. Patients were divided into 2 equal groups (30 subjects). The main group has received citicoline (Ceraxon) as cerebral neuroprotective agent intravenously one day before surgery at a dose of 1000 mg dissolved in 200 ml of 0.9% NaCl, then for 7 days after surgery, followed by oral administration of the drug at a dose of 900 mg/day for 2 months. Comparison group has not received neuroprotective agents in perioperative period. Against the background of treatment with citicoline, the main group has shown persistence of pre-operative level of cognitive functioning according test results, even with improvements in some tests related to subcortical-frontal dysfunction. Comparison group has shown a significant decrease from baseline in cognitive functioning 8-10 days after the surgery, which lasted for a long time. The results allow to consider citicoline (Ceraxon) as a protector of postoperative cognitive dysfunction. It is possible to recommend the inclusion of the drug in the standard scheme of preoperative preparation, and its use in the early postoperative period.
Pharmateca. 2015;(10):55-59
55-59
Effektivnost' probiotikov v povyshenii stomatologicheskogo i somaticheskogo zdorov'ya podrostkov
Abstract
The article presents the results of evaluation of the stomatologic status, local immunity of an oral cavity, and state of health of the teenagers receiving probiotics in the form of dietary supplements. It is established that a probiotics as dietary supplements promote decrease of inflammation of parodontal tissues, increase mucosal immunity of an oral cavity and has beneficial effect on the general health of teenagers.
Pharmateca. 2015;(10):60-62
60-62
Okislitel'nyy stress i perspektivy neyroprotektsii pri khronicheskikh narusheniyakh mozgovogo krovoobrashcheniya
Abstract
The study was aimed to the evaluation of neuroprotective effect of Mildronate in patients with chronic cerebrovascular disease. The dynamics of clinical status and lipid peroxidation in 67 patients with dyscirculatory encephalopathy, the consequences of ischemic stroke on the background of atherosclerosis (22 patients) and moderate arterial hypertension were assesd before and after the 20-day course of treatment with Mildronate at a daily dose of 500 mg parenterally. In the majority of cases treatment with Mildronate had a positive effect on cognitive function, cochle-vestibular, asthenoneurotic and cephalgic syndromes. Experimental data of antioxidant effect of Mildronate, which is realized by increasing endogenous antioxidant status of the organism, were confirmed. It was concluded that Mildronat can be recommended for the use in the treatment of patients with chronic cerebrvascular disease.
Pharmateca. 2015;(10):63-69
63-69
Znachimost' polinenasyshchennykh zhirnykh kislot v kompleksnoy terapii akne
Abstract
The levels of lipid peroxidation (malondialdehyde, diene conjugates) and serum antioxidant system (catalase, glutathione peroxidase) in different clinical forms of acne were determined. The evaluation of the clinical efficacy of the use of polyunsaturated fatty acids (PUFAs) in the complex therapy of acne vulgaris was performed.
Pharmateca. 2015;(10):70-73
70-73
Vliyanie Aktovegina na reparatsiyu khronicheskikh ran razlichnoy etiologii
Abstract
The study was aimed to the evaluation of the effects of the drug Aktovegin in the comprehensive treatment of chronic wounds of various etiologies. The study included 118 patients who were admitted in the Unit of Vascular Surgery and Unit of Surgery of Suppurative Complications of Diabetes Mellitus. Patients were divided into 3 groups depending on etiological factors including pathological conditions that cause the formation of 90% of nonhealing wound defects. Each group was additionally divided into subgroups receiving only conventional therapy and conventional therapy plus Actovegin. The results showed: compared with patients treated with conventional therapy only, in patients treated with Actovegin, reduction of the size of chronic wounds and pain relief was observed 3-4 days and 2-3 days earlier, respectively. The above mentioned allows to recommend the use of Actovegin for the treatment of chronic wounds of various etiologies.
Pharmateca. 2015;(10):74-79
74-79